01—Abstract
Summary
Summary of the 8-K filed September 5, 2024. Cited figures are marked; the original filing is the authoritative source.
McKesson Corporation (MCK) filed an 8-K on September 5, 2024, to provide an update following its participation in the Wells Fargo 2024 Healthcare Conference.
The primary takeaway for investors is that McKesson reaffirmed its full-year fiscal 2025 Adjusted Earnings per Diluted Share (EPS) guidance, which remains in the range of $31.75 to $32.55a. This affirmation suggests confidence in the company's ongoing performance and its ability to meet previously stated financial targets for the fiscal year. Additionally, the company provided an anticipated range for its second quarter fiscal 2025 Adjusted EPS, projecting it to be between $6.70 and $7.00.
This forward-looking statement offers investors a more immediate financial outlook, signaling expected earnings within the current fiscal quarter. The filing also includes standard disclosures regarding non-GAAP financial measures and cautionary statements about forward-looking information, reminding investors of the inherent risks and uncertainties that could impact actual results.
02—Key points
Key Highlights
- McKesson reaffirmed its full-year fiscal 2025 Adjusted Earnings Per Diluted Share (EPS) guidance of $31.75 to $32.55.
- The company anticipates second quarter fiscal 2025 Adjusted EPS to be in the range of $6.70 to $7.00.
- The update was provided during the Wells Fargo 2024 Healthcare Conference.
- The filing includes a detailed definition of their Non-GAAP financial measure, Adjusted Earnings per Diluted Share.
- McKesson stated it cannot provide a quantitative reconciliation of forward-looking Non-GAAP measures to GAAP measures without unreasonable effort due to unpredictability of certain items.
- The report contains standard cautionary statements regarding forward-looking statements and associated risks.
03—Questions
Frequently Asked Questions
What is McKesson's updated financial outlook for the full fiscal year 2025?
McKesson reaffirmed its full-year fiscal 2025 Adjusted Earnings per Diluted Share guidance, expecting it to be in the range of $31.75 to $32.55.
What are McKesson's expectations for the second quarter of fiscal 2025?
The company anticipates its Adjusted Earnings per Diluted Share for the second quarter of fiscal 2025 to be between $6.70 and $7.00.
Why does McKesson provide guidance on a Non-GAAP basis (Adjusted EPS) rather than GAAP?
McKesson states that it is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure without unreasonable effort. This is because certain items such as LIFO inventory adjustments, litigation contingencies, and restructuring charges are difficult to predict and estimate, and their impact on GAAP performance could vary materially.
What are the main risks associated with McKesson's forward-looking statements?
McKesson's filing lists several risks, including costly legal disputes and settlements (e.g., related to opioid distribution), potential uninsured losses, complex and changing healthcare laws, impairment charges, cybersecurity incidents, failure to achieve growth objectives, customer payment issues, risks with government contracts, supplier relationship changes, data services limitations, healthcare reform impacts, competition, product supply disruptions, generic pharmaceutical distribution risks, economic and capital market changes, tax legislation changes, and events outside of their control like public health issues or natural disasters.
04—Continue